Lataa...
The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer
Triple negative breast cancer (TNBC) is an aggressive subtype that accounts for 15-20% of cases, with a higher incidence of relapse/death. Even with adjuvant chemotherapy, the 5 year distant metastasis-free survival rate remains low. A total of 452 tumor registry patients with TNBC and no evidence o...
Tallennettuna:
| Julkaisussa: | Oncotarget |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Impact Journals LLC
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5762543/ https://ncbi.nlm.nih.gov/pubmed/29348858 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22521 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|